Divalproex Sodium Tablet, Extended Release
Product Images NDC 70518-3183

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 70518-3183). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Divalproex Sodium Extended-Release 250 mg is a medication in tablet form that is only available by prescription. It is manufactured by Lupin Pharma in Baltimore, MD, and repackaged by RemedyRepack Inc. in Indiana, PA. The prescription label includes the NDC # 70518-3183-00 and instructions to keep the medication out of reach of children. It also indicates that the medication should be stored in a cool, dry place, with permitted excursions from 15-30°C (59-86°F), and buyers should refer to the package insert for specific instructions. No expiration or lot number are provided.*

FDA Label Image

Image 1 (D95f9b1b F1e4 4ae4 A215 7317fb1ca565 01)

FDA Label Image

Image 2 (D95f9b1b F1e4 4ae4 A215 7317fb1ca565 02)

The text appears to show a chart displaying the percentage reduction in CPS rate for patients taking Divalproex Sodium Delayed-Release compared to a placebo. The chart shows a 50% improvement in some patients, while others experienced no change or worsening.*

FDA Label Image

Image 3 (D95f9b1b F1e4 4ae4 A215 7317fb1ca565 03)

FDA Label Image

Image 4 (D95f9b1b F1e4 4ae4 A215 7317fb1ca565 04)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.